Additional file 5 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-��5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Additional file 5. Percent of Participants with Relevant Improvements for each Assessment of the Composite Endpoint by Age Group at 3 and 6 months. A table showing percent of participants with above-threshold improvements for each assessment by age group and time point.